Digest Network Come funziona
Network
/
Società
Am
Non verificato

Amylyx Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

53 comunicati stampa

Guarda tutti i comunicati
07/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
Fonte
Amylyx Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/05/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
Fonte
Amylyx Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Industria
Salute
Sanità
Medicina - Varie
Farmaceutica
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
Fonte
Amylyx Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Fonte
Amylyx Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/04/2026
Web e Social Network
Fiere
Eventi
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Fonte
Amylyx Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
24/03/2026
Industria
Biotecnologia
Farmaceutica
Sanità
Medicina - Varie
Salute
Fitness
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Fonte
Amylyx Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/03/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Fonte
Amylyx Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
26/02/2026
Web e Social Network
Eventi
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
Fonte
Amylyx Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
24/02/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
Fonte
Amylyx Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Biotecnologia
Farmaceutica
Sanità
Medicina - Varie
Salute
Fitness
Mercato del lavoro
Industria
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
Fonte
Amylyx Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0